

Claim 6 (original): The method of claim 5, wherein the anti-gp39 antibody is a monoclonal antibody.

Claim 7 (original): The method of claim 5, wherein the anti-gp39 antibody is an anti-human gp39 antibody.

Claim 8 (previously amended): The method of claim 6, wherein the monoclonal antibody is 89-76 or 24-31, or an antibody having the gp39 binding characteristics thereof.

Claim 9 (previously amended): The method of claim 6, wherein the monoclonal antibody is a chimeric monoclonal antibody containing constant regions and variable regions from different species.

Claim 10 (original): The method of claim 6, wherein the monoclonal antibody is a humanized monoclonal antibody.

Claim 11 (canceled)

Claim 12 (currently amended): The method of claim 1, wherein the gp39 antagonist is an anti-gp39 antibody or a gp39-binding fragment thereof, comprising variable regions of monoclonal antibody 24-31 or monoclonal antibody 89-76, ~~or of an antibody having the gp39 binding characteristics thereof.~~

Claim 13 (previously added): The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment comprising variable regions of monoclonal antibody 24-31.

Claim 14 (previously added): The method of claim 13, wherein the gp39-binding antibody fragment is a Fab or F(ab')₂ fragment comprising variable regions of monoclonal antibody 24-31.

Claim 15 (previously added): The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment comprising variable regions of monoclonal antibody 89-76.

Claim 16 (previously added): The method of claim 15, wherein the gp39-binding antibody fragment is a Fab or F(ab')₂ fragment comprising variable regions of monoclonal antibody 89-76.

Claim 17 (previously added): The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

Claim 18 (previously added): The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 89-76.

Claim 19 (previously added): The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

Claim 20 (previously added): The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 89-76.

Claim 21 (new): The method of claim 1, wherein tissue destruction associated with type I diabetes in the subject results from a cell-mediated immune reaction to a self-antigen and not from a humoral immune reaction.

II. REMARKS

Preliminary Remarks

The first paragraph of the specification is amended to state the current status of the parent applications, as requested in the office action.

Claim 1 is amended to be directed to a method for inhibiting or preventing T cell mediated tissue destruction associated with type I diabetes consisting essentially of administering to a subject in need of such treatment a therapeutically or prophylactically effective amount of gp39 antagonist, wherein said tissue destruction results from a cell-mediated immune reaction to a self-antigen (emphasis added). New claim 21 is similarly directed to the method of claim 1, wherein tissue destruction associated with type I diabetes in the subject results from a cell-mediated immune reaction to a self-antigen and not from a humoral immune reaction to a self-antigen wherein tissue destruction associated with type I diabetes in the subject results from a cell-mediated immune reaction to a self-antigen and not from a humoral immune reaction. Support for the amendment of claim 1 and for new claim 21 is found in the specification, for example, in the paragraph at the bottom of page 3, which states that T cell mediated autoimmune disorders that are treated by the methods of the